Amsterdam-based DEBx Medical, a medtech company that improves the quality of life of millions of people suffering from chronic wounds, announced on Monday, May 22, that it has raised €10M in a fresh round of funding.
DEBx Medical says it will use the funds to commercialise its flagship product DEBRICHEM for the benefit of patients.
The Dutch startup will also build a regional headquarters and a manufacturing base in the MENA region, increasing the region’s adoption of its “innovative” wound care solution.
The investor
The investment came from TVM Capital Healthcare’s Afiyah Fund. TVM Capital Healthcare is a global specialist healthcare private equity firm based out of Dubai and Singapore.
Tristan de Boysson, Managing Partner of TVM Capital Healthcare, says, “With this investment from our TVM Healthcare Afiyah Fund, we will accelerate the market introduction of a product which will transform the management of chronic wounds, and improve the lives of millions of patients.”
“This investment is also part of our Fund’s strategy of bringing innovative, best-in-class healthcare solutions to the wider MENA region. We are looking forward to working together with the DEBx Medical management team.”
Diagnostics and therapy for chronic wounds
According to DEBx Medical, chronic wounds are a serious healthcare concern, affecting around 2.4 per cent of the population during their lifetime, and are especially prevalent in Gulf Cooperation Council (GCC) nations where diabetes contributes to the problem.
Hard-to-heal wounds can lead to poor patient health and quality of life outcomes, as well as a significant expense to healthcare systems.
This is where DEBx Medical looks to make a difference.
Founded in 2019 by Bert J. Quint, Prof. Dr Carlo Alberto Bignozzi, and MD Alberto Cogo, DEBx Medical’s goal is to develop and sell a single treatment to eradicate wound infection.
The Dutch startup wants to help doctors and their patients from diagnosis to therapy, follow-up care, and wound bed management. The company’s basic beliefs centre on providing low-cost therapies that are simple to use and execute in regular clinical practice.
To do this, DEBx Medical has developed a “groundbreaking” product called DEBRICHEM that provides a superior alternative to current therapies for non-healing chronic wounds.
The product is designed for topical treatment of an infected wound, to help facilitate the removal of the infection by debridement, followed by cleaning and dressing.
Bert Quint says, “Our product, DEBRICHEM, has the potential to disrupt the chronic wound care market and help patients to heal fast, safely and effectively. After just one single treatment, more than 90 per cent of chronic wounds start healing.”
DEBRICHEM is an acidic gel certified as a single-use medical device. It removes biofilm and heals wounds that are difficult to cure and is also simple to use. DEBx Medical, which received CE and ISO clearances in February 2021, has treated more than 5,000 patients and is all set to launch its product in the market.
About TVM Capital Healthcare
TVM Capital Healthcare is a healthcare private equity firm. It invests expansion and growth capital in healthcare companies with a focus on specialised and tech-enabled healthcare services, digital health solutions and platforms.
The firm also invests in manufacturing companies in pharmaceuticals, medical devices, and diagnostics.
TVM collaborates with local management teams in the Middle East and Southeast Asia to establish domestic or regional sector champions, and it selectively backs firms from Europe or North America for expansion into the firm’s target areas.
TVM’s investment and operating strategy combines commercial value creation and returns with ethical investing and a thorough ESG framework to build impactful, sustainable, and well-governed businesses that provide top-notch healthcare services while continuing to grow and create jobs in a fair and diverse workplace.
01
How Gen Z affects B2B social media